Multimode microplate
01 January, 2009 | Supplied by: Ai Scientific Pty Ltd
Tecan’s range of multimode microplate readers includes the Infinite M1000 and Infinite F500, which are certified for compatibility with the Promega Dual-Luciferase Assay.
Diagnostic test for ovarian cancer
01 January, 2009 | Supplied by: Manalto Inc
The OvPlex Panel is an early detection test for ovarian cancer, developed by HealthLinx in collaboration with ARL Pathology.
Breast cancer gene-expression blood test
01 January, 2009 | Supplied by: Applied Biosystems Pty Ltd
DiaGenic and Applied Biosystems have launched BCtect, a blood-based test for early detection of breast cancer. The test searches for a unique gene expression signature using a custom TaqMan array.
Whole transcriptome amplification
01 January, 2009 | Supplied by: Merck
Sigma-Aldrich has launched the TransPlex Whole Transcriptome Amplification (WTA2) technology. TransPlex technology is said to be a fast, sensitive and robust method for amplifying total RNA from a variety of sample tissue sources such as animals, plants and microorganisms.
Stem cell cytometry kits
01 January, 2009 | Supplied by: Merck Pty Limited
Millipore has launched six flow cytometry kits for stem cell research. The robust, three-parameter FlowCellect kits allow scientists to assess embryonic and neural stem cell phenotypes at various stages of differentiation.
Labware loading racks
01 January, 2009 | Supplied by: Keysight Technologies Australia Pty Ltd
Velocity11 has expanded the range of Labware Racks available for its BenchCel Microplate Handling System and VStack Labware Stacker.
Cancer diagnostic tests
01 January, 2009 | Supplied by: bioMerieux Australia
AviaraDx’s diagnostic tests can be used in the molecular classification of cancers and to assist oncologists in making therapeutic decisions.
Spectral scanning microplate reader
01 January, 2009 | Supplied by: Pathtech Pty Ltd
The Thermo Scientific Varioskan Flash Microplate Reader is a spectral scanning multimode reader with fluorescence intensity, time-resolved fluorescence (TRF) and both photometric and luminometric detection technologies.
Faecal occult blood test
01 December, 2008 | Supplied by: Alere Australia
The ColonView quick test from Biohit can be used for identification of patients with faecal occult blood, a known marker for colorectal cancer and pre-cancerous large adenomas. ColonView testing can also give information on other possible diseases of the gastrointestinal tract that are associated with bleeding.
PSA/fPSA immunoassay analysis
01 December, 2008 | Supplied by: Olympus Australia Pty Ltd
Olympus has released PSA and fPSA assays for the Olympus AU3000i immunoassay analyser. The assays feature assay sensitivity of 0.015 µg/L. In the monitoring of patients after prostate cancer treatment, the sensitive PSA assay is suitable for the detection of recurrence of the disease.
Big demand for biochips
11 November, 2008
Ten percent plus growth is forecast for the biochip market in the US, with demand being led from the drug discovery sector.
Australian gene technology launched in US
10 November, 2008
A microarray that consists of both mRNA and non-coding RNA content which helps to elucidate the function of specific non-coding RNAs in relation to known pathways of gene expression has been invented at UQ and now marketed to the US.
Automated gentle tissue dissociator
08 September, 2008 | Supplied by: http://www.miltenyibiotec.com
The gentleMACS dissociator is a benchtop instrument for the automated dissociation of tissues. The instrument offers programs for a variety of specific applications.
Urine chemistry analyser
01 September, 2008 | Supplied by: Siemens Ltd
The Siemens Healthcare Diagnostics Clinitek Advantus Urine chemistry analyser enables automated reading of Siemens’ Multistix family of urinalysis testing strips in medium to high throughput settings.
Rapid tests for drug-resistant TB
01 September, 2008
People in low-resource countries who are ill with multidrug-resistant TB (MDR-TB) will get a faster diagnosis — in two days, not the standard two to three months — and appropriate treatment due to two initiatives by WHO, the Stop TB Partnership, UNITAID and the Foundation for Innovative New Diagnostics (FIND).
